MSC1094308 is a reversible, non-ATP-competitive, type I AAA ATPase VPS4B-selective allosteric inhibitor (IC50 = 0.71 µM) with =10-fold reduced potency toward the type II AAA ATPase VCP/p97 and NSF (IC50 = 7.2 and >40 µM, respectively). MSC1094308 specifically inhibits p97-mediated Ub-GFP degradation without affecting proteasome-dependent ODD-luc degradation using a dual reporter HeLa cell line (10 µM) and exhibits comparable efficacy as DBeQ against 50 ng/mL TNFα-induced IκBα degradation in HeLa cells (10 µM).
MSC1094308 binding to drugable hotspot of p97 has the ability to block the D2 ATPase activity.